Alto Neuroscience, Inc. ANRO 深 沪
已收盘 05-15 16:00:00 美东时间
22.98
-0.610
-2.59%
华盛通- 最 高23.50
- 今 开23.04
- 成交量 37.63万股
- 最 低 22.41
- 昨 收 23.59
- 总市值 7.34亿
- 52周最高 28.441
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 2.15
- 委 比 90.00%
- 总股本 3194.55万
- 历史最高 28.441
- 量 比 1.11
- 振 幅 4.62%
- 历史最低 1.60
- 每 手 1
- 风险率 8.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.54) by 48.15 percent. This is a 42.86 percent decrease over losses of $(0.56) per share from
05-13 19:25
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $50 price target.
05-12 01:38
Alto Neuroscience Presents Data On Its Phase 2a Study Of ALTO-207 In Participants With Major Depressive Disorder At 2026 Annual Meeting Of Society Of Biological Psychiatry
Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind,
05-04 20:11
Alto Neuroscience Initiates Phase 2b Trial Of ALTO-207
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies —— Trial design and MADRS primary endpoint aligned with FDA
04-21 20:09
Alto Neuroscience Files Prospectus For Resale Of 6M Shares, Company To Receive Proceeds Only From Pre-Funded Warrants
6,000,000 SharesCommon Stock Offered by the Selling StockholdersThis prospectus relates to the proposed resale from time to time of up to 6,000,000 shares, or the Shares, of our common stock, par value $0.0001 per share,
04-11 04:25
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
Alto Neuroscience shares are trading lower after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.
Alto Neuroscience shares are trading lower after the company announced topline ...
04-02 04:34
Alto Neuroscience Announces Topline Data From Phase 2 POC Clinical Trial Evaluating ALTO-101 For Treatment Of CIAS; ALTO-101 Did Not Achieve Statistical Significance On Primary EEG Or Cognitive Endpoints Versus Placebo
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) —— Alto has
04-02 04:32
